Beijing
China
26
2025-06-26
The entities that hold a legal rights for patent applications filed by inventor Wang Hexiang:
Hexiang Wang from Beijing, CN has applied for patents for these inventions. The list has both pending applications and granted patents:
DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
#2 | 2025-01-30NUCLEOSIDE-DIPHOSPHATE-HEPTOSE COMPOUNDS FOR TREATING CONDITIONS ASSOCIATED WITH ALPK1 ACTIVITY
#3 | 2024-11-07DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
#4 | 2024-11-07DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
#5 | 2024-07-25DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHOD OF USE
#6 | 2023-10-12DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
#7 | 2023-06-01DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
#8 | 2022-09-08DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
#9 | 2022-07-21AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES
#10 | 2021-07-08MAINTENANCE THERAPY OF A PARP INHIBITOR IN TREATING GASTRIC CANCER
#11 | 2020-10-08Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases
#12 | 2020-07-16Self-propelled soft robot body
#13 | 2020-05-21Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
#14 | 2020-05-21TREATMENT OF CANCERS USING A COMBINATION COMPRISING PARP INHIBITORS, TEMOZOLOMIDE AND/OR RADIATION THERAPY
#15 | 2020-01-30Treatment cancers using a combination comprising PARP inhibitors
#16 | 2020-01-235 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenases
#17 | 2019-09-195 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases
#18 | 2019-06-13Process for preparing a PARP inhibitor, crystalline forms, and uses thereof
#19 | 2019-01-17Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors
#20 | 2018-03-155 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases
#21 | 2017-10-26Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors
#22 | 2017-02-02Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
#23 | 2016-06-09Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors
#24 | 2016-02-04Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
#25 | 2015-06-25Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors
#26 | 2015-01-15Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors
1037500 ⎘